MA52131A - Utilisation de la taille des fragments d'adn libres dans les cellules pour déterminer des variations du nombre de copies - Google Patents

Utilisation de la taille des fragments d'adn libres dans les cellules pour déterminer des variations du nombre de copies

Info

Publication number
MA52131A
MA52131A MA052131A MA52131A MA52131A MA 52131 A MA52131 A MA 52131A MA 052131 A MA052131 A MA 052131A MA 52131 A MA52131 A MA 52131A MA 52131 A MA52131 A MA 52131A
Authority
MA
Morocco
Prior art keywords
copies
cells
size
dna fragments
free dna
Prior art date
Application number
MA052131A
Other languages
English (en)
Inventor
Catalin Barbacioru
Gengxin Chen
Darya I Chudova
David A Comstock
Sven Duenwald
Keith W Jones
Richard P Rava
Dimitri Skvortsov
Original Assignee
Verinata Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verinata Health Inc filed Critical Verinata Health Inc
Publication of MA52131A publication Critical patent/MA52131A/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/23—Clustering techniques
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/24—Classification techniques
    • G06F18/243—Classification techniques relating to the number of classes
    • G06F18/24323—Tree-organised classifiers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Signal Processing (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
MA052131A 2016-02-03 2016-12-20 Utilisation de la taille des fragments d'adn libres dans les cellules pour déterminer des variations du nombre de copies MA52131A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662290891P 2016-02-03 2016-02-03

Publications (1)

Publication Number Publication Date
MA52131A true MA52131A (fr) 2019-07-31

Family

ID=57583028

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052131A MA52131A (fr) 2016-02-03 2016-12-20 Utilisation de la taille des fragments d'adn libres dans les cellules pour déterminer des variations du nombre de copies
MA044822A MA44822A (fr) 2016-02-03 2016-12-20 Utilisation de la taille des fragments d'adn extracellulaire pour déterminer des variations du nombre de copies

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA044822A MA44822A (fr) 2016-02-03 2016-12-20 Utilisation de la taille des fragments d'adn extracellulaire pour déterminer des variations du nombre de copies

Country Status (20)

Country Link
US (3) US10095831B2 (fr)
EP (2) EP3517626B1 (fr)
KR (2) KR102184868B1 (fr)
CN (2) CN113096726B (fr)
AR (1) AR107192A1 (fr)
AU (2) AU2016391100B2 (fr)
BR (1) BR112018015913B1 (fr)
CA (1) CA3013572C (fr)
CY (1) CY1121741T1 (fr)
DK (1) DK3202915T3 (fr)
EA (2) EA035148B1 (fr)
IL (2) IL260938B (fr)
MA (2) MA52131A (fr)
NZ (1) NZ745637A (fr)
SA (1) SA518392138B1 (fr)
SG (1) SG11201806595UA (fr)
TW (2) TWI708848B (fr)
UA (1) UA126898C2 (fr)
WO (1) WO2017136059A1 (fr)
ZA (1) ZA201805753B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093330A1 (fr) 2012-12-10 2014-06-19 Clearfork Bioscience, Inc. Procédés pour analyse génomique ciblée
WO2015061359A1 (fr) 2013-10-21 2015-04-30 Verinata Health, Inc. Procédé destiné à l'amélioration de la sensibilité de détection dans la détemrination des variations du nombre de copies
US10318704B2 (en) 2014-05-30 2019-06-11 Verinata Health, Inc. Detecting fetal sub-chromosomal aneuploidies
CA2970501C (fr) 2014-12-12 2020-09-15 Verinata Health, Inc. Utilisation de la taille de fragments d'adn acellulaire pour determiner les variations du nombre de copies
MX2018005858A (es) 2015-11-11 2019-02-20 Resolution Bioscience Inc Construccion de alta eficacia de bibliotecas de adn.
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
US11514289B1 (en) * 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
WO2018031739A1 (fr) * 2016-08-10 2018-02-15 New York Genome Center, Inc. Séquençage de génome à ultra-faible couverture et ses utilisations
WO2018039463A1 (fr) 2016-08-25 2018-03-01 Resolution Bioscience, Inc. Procédés de détection de changements de copie génomique dans des échantillons d'adn
EP3559841A1 (fr) 2016-12-22 2019-10-30 Grail, Inc. Normalisation de couverture de base et son utilisation pour détecter une variation du nombre de copies
TWI803477B (zh) * 2017-01-25 2023-06-01 香港中文大學 使用核酸片段之診斷應用
US11342047B2 (en) 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
AU2018355575A1 (en) 2017-10-27 2020-05-21 Juno Diagnostics, Inc. Devices, systems and methods for ultra-low volume liquid biopsy
GB201718620D0 (en) * 2017-11-10 2017-12-27 Premaitha Ltd Method of detecting a fetal chromosomal abnormality
KR20210009299A (ko) * 2018-02-27 2021-01-26 코넬 유니버시티 게놈-와이드 통합을 통한 순환 종양 dna의 초민감 검출
EP3765633A4 (fr) * 2018-03-13 2021-12-01 Grail, Inc. Procédé et système de sélection, de gestion et d'analyse de données de dimensionnalité élevée
US20190295684A1 (en) * 2018-03-22 2019-09-26 The Regents Of The University Of Michigan Method and apparatus for analysis of chromatin interaction data
EP3773534A4 (fr) * 2018-03-30 2021-12-29 Juno Diagnostics, Inc. Procédés, dispositifs et systèmes basés sur l'apprentissage profond pour le dépistage anténatal
JP6974504B2 (ja) 2018-04-02 2021-12-01 イルミナ インコーポレイテッド 配列に基づく遺伝子試験のための対照を作製するための組成物及び方法
CA3096678A1 (fr) * 2018-04-13 2019-10-17 Grail, Inc. Modele de prediction de dosages multiples pour la detection du cancer
TW202410055A (zh) 2018-06-01 2024-03-01 美商格瑞爾有限責任公司 用於資料分類之卷積神經網路系統及方法
US11574706B2 (en) * 2018-06-28 2023-02-07 10X Genomics, Inc. Systems and methods for visualization of single-cell resolution characteristics
JP6891150B2 (ja) * 2018-08-31 2021-06-18 シスメックス株式会社 解析方法、情報処理装置、遺伝子解析システム、プログラム、記録媒体
US11610150B2 (en) 2018-10-09 2023-03-21 Ferrum Health, Inc. Method for computing performance in multiple machine learning classifiers
US11488716B2 (en) * 2018-10-09 2022-11-01 Ferrum Health, Inc. Method for configuring multiple machine learning classifiers
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
CA3119980A1 (fr) * 2018-12-20 2020-06-25 Guardant Health, Inc. Procedes, compositions et systemes pour ameliorer la recuperation de molecules d'acide nucleique
WO2020127629A1 (fr) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Identification de caractéristiques de séquence globale dans des données de séquence de génome complet à partir d'acide nucléique circulant
KR102287096B1 (ko) * 2019-01-04 2021-08-09 테라젠지놈케어 주식회사 모체 시료 중 태아 분획을 결정하는 방법
CA3115513A1 (fr) * 2019-06-03 2020-12-10 Illumina, Inc. Limite de metrique de controle qualite basee sur la detection
CN110373477B (zh) * 2019-07-23 2021-05-07 华中农业大学 克隆自cnv片段的与猪耳形性状相关的分子标记
CN110570902B (zh) * 2019-08-27 2023-05-23 深圳百诺精准医疗科技有限公司 一种拷贝数变异分析方法、系统及计算机可读存储介质
EP4035161A1 (fr) 2019-09-23 2022-08-03 Grail, LLC Systèmes et procédés pour diagnostiquer un état pathologique à l'aide de données de séquençage sur cible et hors cible
CN115298324A (zh) * 2019-12-18 2022-11-04 香港中文大学 游离dna断裂和核酸酶
CN111028890B (zh) * 2019-12-31 2020-09-11 东莞博奥木华基因科技有限公司 一种基于run间矫正的CNV检测方法
CN111210873B (zh) * 2020-01-14 2023-03-28 西安交通大学 基于外显子测序数据的拷贝数变异检测方法及系统、终端和存储介质
EP4069864A4 (fr) * 2020-02-05 2023-01-25 The Chinese University Of Hong Kong Analyses moléculaires utilisant de longs fragments acellulaires pendant la grossesse
CN111477275B (zh) * 2020-04-02 2020-12-25 上海之江生物科技股份有限公司 微生物目标片段中多拷贝区域的识别方法、装置及应用
CN111411144B (zh) * 2020-04-21 2023-12-22 深圳华大因源医药科技有限公司 一种用于血流感染病原诊断的血浆游离dna标志物
CN113593637B (zh) * 2020-04-30 2024-05-03 深圳市真迈生物科技有限公司 测序方法及其分析方法和系统、计算机可读存储介质和电子设备
KR20220074088A (ko) * 2020-11-27 2022-06-03 주식회사 지씨지놈 인공지능 기반 암 진단 및 암 종 예측방법
WO2022119812A1 (fr) 2020-12-02 2022-06-09 Illumina Software, Inc. Système et procédé pour la détection d'altérations génétiques
CN112766428B (zh) * 2021-04-08 2021-07-02 臻和(北京)生物科技有限公司 肿瘤分子分型方法及装置、终端设备及可读存储介质
CN113270138B (zh) * 2021-04-13 2023-09-22 杭州博圣医学检验实验室有限公司 基于生物信息学富集胎儿游离dna用于拷贝数变异的分析方法
CN113889187B (zh) * 2021-09-24 2022-12-06 上海仁东医学检验所有限公司 单样本等位基因拷贝数变异检测方法、探针组和试剂盒
EP4413156A1 (fr) * 2021-10-08 2024-08-14 Foundation Medicine, Inc. Procédés et systèmes pour la détection automatisée des altérations du nombre de copies
KR20230114952A (ko) * 2022-01-26 2023-08-02 권창혁 암 판별 장치 및 암 판별 방법
WO2023192942A1 (fr) * 2022-03-31 2023-10-05 Illumina, Inc. Appel de variant de nombre de copies pour répétition de lpa kiv-2
CN114464269B (zh) * 2022-04-07 2022-07-08 国家超级计算天津中心 一种虚拟药物生成方法、装置及计算机设备
WO2024044749A1 (fr) * 2022-08-26 2024-02-29 Fred Hutchinson Cancer Center Techniques d'analyse de données de séquence d'adn acellulaire pour estimer une fraction fœtale et prédire une pré-éclampsie
WO2024173756A1 (fr) 2023-02-17 2024-08-22 Illumina, Inc. Signaux d'adn acellulaire utilisés en tant que biomarqueurs de la prééclampsie
CN116597893B (zh) * 2023-06-14 2023-12-15 北京金匙医学检验实验室有限公司 预测耐药基因-病原微生物归属的方法
CN117116344B (zh) * 2023-10-25 2024-07-19 北京大学第三医院（北京大学第三临床医学院） 一种单细胞水平pmp22重复变异的检测系统和方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216153A1 (en) 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
WO2007145612A1 (fr) 2005-06-06 2007-12-21 454 Life Sciences Corporation Séquençage d'extrémités appariées
WO2008045505A2 (fr) 2006-10-10 2008-04-17 Xenomics, Inc. Compositions, procédés et trousses pour isoler acides nucléiques à partir de fluides corporels au moyen d'un milieu d'échange anionique
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
EP3770275A1 (fr) 2007-07-23 2021-01-27 The Chinese University of Hong Kong Détermination d'une aneuploïdie fétale
CN101889074A (zh) 2007-10-04 2010-11-17 哈尔西恩莫尔丘勒公司 采用电子显微镜对核酸聚合物测序
WO2009051842A2 (fr) 2007-10-18 2009-04-23 The Johns Hopkins University Détection d'un cancer par mesure du nombre de copies génomiques et de la longueur des brins dans de l'adn exempt de cellules
CA2704118A1 (fr) 2007-11-01 2009-05-07 The Hospital For Sick Children Procede de determination du risque cancereux
LT2562268T (lt) 2008-09-20 2017-04-25 The Board Of Trustees Of The Leland Stanford Junior University Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu
US8620593B2 (en) 2009-11-06 2013-12-31 The Chinese University Of Hong Kong Size-based genomic analysis
US9323888B2 (en) * 2010-01-19 2016-04-26 Verinata Health, Inc. Detecting and classifying copy number variation
US9260745B2 (en) 2010-01-19 2016-02-16 Verinata Health, Inc. Detecting and classifying copy number variation
EP2526415B1 (fr) 2010-01-19 2017-05-03 Verinata Health, Inc Procédés de détection définis par des partitions
EP2591433A4 (fr) 2010-07-06 2017-05-17 Life Technologies Corporation Systèmes et procédés pour détecter une variation de nombre de copies
US9029103B2 (en) 2010-08-27 2015-05-12 Illumina Cambridge Limited Methods for sequencing polynucleotides
US8725422B2 (en) * 2010-10-13 2014-05-13 Complete Genomics, Inc. Methods for estimating genome-wide copy number variations
MX349568B (es) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
US9411937B2 (en) 2011-04-15 2016-08-09 Verinata Health, Inc. Detecting and classifying copy number variation
ES2605372T3 (es) 2011-05-31 2017-03-14 Berry Genomics Co., Ltd. Un dispositivo para detectar el número de copias de cromosomas fetales o cromosomas de células tumorales
PL2561103T3 (pl) 2011-06-29 2015-02-27 Bgi Diagnosis Co Ltd Nieinwazyjna detekcja anomalii genetycznych płodu
EP2563937A1 (fr) 2011-07-26 2013-03-06 Verinata Health, Inc Procédé de détermination de la présence ou de l'absence d'aneuploïdes différents dans un échantillon
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP6073902B2 (ja) 2011-10-06 2017-02-01 セクエノム， インコーポレイテッド 遺伝的変異の非侵襲的評価のための方法およびプロセス
ES2741966T3 (es) 2011-12-31 2020-02-12 Bgi Genomics Co Ltd Método para detectar una variación genética
EP2805280B1 (fr) 2012-01-20 2022-10-05 Sequenom, Inc. Processus de diagnostic qui tiennent compte des conditions d'expérimentation
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
EP3573066B1 (fr) 2012-03-13 2023-09-27 The Chinese University Of Hong Kong Procédés d'analyse de données de séquençage massivement parallèles pour diagnostic prénatal non invasif
CN103374518B (zh) * 2012-04-12 2018-03-27 维里纳塔健康公司 拷贝数变异的检测和分类
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
EP2875149B1 (fr) 2012-07-20 2019-12-04 Verinata Health, Inc. Détection et classification de variation du nombre de copies dans un génome de cancer
US20140066317A1 (en) * 2012-09-04 2014-03-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
WO2014039556A1 (fr) * 2012-09-04 2014-03-13 Guardant Health, Inc. Systèmes et procédés pour détecter des mutations rares et une variation de nombre de copies
EP2900835A4 (fr) 2012-09-27 2016-05-11 Population Diagnotics Inc Procédés et compositions de dépistage et de traitement de troubles du développement
CN105408496A (zh) 2013-03-15 2016-03-16 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
CA2915626A1 (fr) * 2013-06-17 2014-12-24 Verinata Health, Inc. Methode pour determiner les variations du nombre de copies dans des chromosomes sexuels
SI3011051T1 (sl) 2013-06-21 2019-05-31 Sequenom, Inc. Postopek za neinvazivno oceno genetskih variacij
WO2015061359A1 (fr) 2013-10-21 2015-04-30 Verinata Health, Inc. Procédé destiné à l'amélioration de la sensibilité de détection dans la détemrination des variations du nombre de copies
US10415083B2 (en) 2013-10-28 2019-09-17 The Translational Genomics Research Institute Long insert-based whole genome sequencing
US10318704B2 (en) 2014-05-30 2019-06-11 Verinata Health, Inc. Detecting fetal sub-chromosomal aneuploidies
CA2970501C (fr) 2014-12-12 2020-09-15 Verinata Health, Inc. Utilisation de la taille de fragments d'adn acellulaire pour determiner les variations du nombre de copies
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
WO2016134452A1 (fr) 2015-02-26 2016-09-01 Titan Medical Inc. Procédé et appareil pour fournir un accès pour une procédure chirurgicale
US10095831B2 (en) * 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
US11342047B2 (en) 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant

Also Published As

Publication number Publication date
DK3202915T3 (da) 2019-06-24
US20230044849A1 (en) 2023-02-09
EA201891580A1 (ru) 2019-01-31
KR20180123020A (ko) 2018-11-14
UA126898C2 (uk) 2023-02-22
EA202090277A2 (ru) 2020-07-31
CN113096726B (zh) 2024-04-26
EA202090277A3 (ru) 2020-10-30
NZ745637A (en) 2019-05-31
EP3202915B1 (fr) 2019-03-20
TW201930598A (zh) 2019-08-01
US20190065676A1 (en) 2019-02-28
EA035148B1 (ru) 2020-05-06
WO2017136059A1 (fr) 2017-08-10
SA518392138B1 (ar) 2024-01-29
EP3202915A1 (fr) 2017-08-09
KR102049191B1 (ko) 2019-11-26
CY1121741T1 (el) 2020-07-31
KR20190132558A (ko) 2019-11-27
EP3517626B1 (fr) 2024-02-07
CA3013572C (fr) 2023-01-17
CN113096726A (zh) 2021-07-09
CN108884491B (zh) 2021-04-27
IL260938B (en) 2020-03-31
TWI661049B (zh) 2019-06-01
MA44822A (fr) 2017-08-09
AU2016391100B2 (en) 2019-03-07
AU2016391100A1 (en) 2018-09-27
AR107192A1 (es) 2018-03-28
US11430541B2 (en) 2022-08-30
US20170220735A1 (en) 2017-08-03
CN108884491A (zh) 2018-11-23
TWI708848B (zh) 2020-11-01
ZA201805753B (en) 2019-04-24
IL272710A (en) 2020-04-30
KR102184868B1 (ko) 2020-12-02
AU2019203491A1 (en) 2019-06-06
US10095831B2 (en) 2018-10-09
NZ752319A (en) 2021-01-29
BR112018015913A2 (pt) 2019-01-22
EP3517626C0 (fr) 2024-02-07
TW201805429A (zh) 2018-02-16
BR112018015913B1 (pt) 2019-12-03
SG11201806595UA (en) 2018-09-27
IL272710B (en) 2021-05-31
EP3517626A1 (fr) 2019-07-31
AU2019203491B2 (en) 2021-05-27
CA3013572A1 (fr) 2017-08-10

Similar Documents

Publication Publication Date Title
MA52131A (fr) Utilisation de la taille des fragments d'adn libres dans les cellules pour déterminer des variations du nombre de copies
DK3604527T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
DK3574108T3 (da) Diagnostisk anvendelse ved brug af nukleinsyrefragment
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
DK3354661T3 (da) Fuldstændigt humant antistof mod human CD137 og anvendelse deraf
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
EA201692498A1 (ru) Способы сбора культур клеток млекопитающих
MA43053A (fr) Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA41433A (fr) Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA51649A (fr) Culture de placenta pour isoler des exosomes
DK3292271T3 (da) Anvendelse af den naturlige lave radioaktivitet af råmaterialer til evaluering af grusfilter- og cementplacering i brønde
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA43588A (fr) Protéines de fusion follistatine-fc recombinantes et leur utilisation dans le traitement de la dystrophie musculaire de duchenne
MA39096B1 (fr) Anticorps spécifiques à fcrn
DK3167080T3 (da) Analyse af genetisk afhængighedsrisiko til rds-sværhedsindeks og kit
FR3036221B1 (fr) Structure d'interconnexion de cellules memoire jumelles
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA39502A (fr) Constructions d'expression et méthodes de sélection des cellules hôtes exprimant des polypeptides
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
DK3283658T3 (da) Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
MA44379A (fr) Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation
FR3030515B1 (fr) Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines